Fortress Biotech (FBIOP) Financials

Fortress Biotech logo
$13.85 -0.51 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$13.93 +0.08 (+0.58%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Fortress Biotech

Annual Income Statements for Fortress Biotech

This table shows Fortress Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-48 -55 -67 -84 -40 -47 -65 -95 -69 -56 -1.88
Consolidated Net Income / (Loss)
-54 -71 -100 -142 -102 -103 -165 -214 -154 -121 -33
Net Income / (Loss) Continuing Operations
-113 -41 -98 -131 -102 -103 -165 -214 -154 -121 -33
Total Pre-Tax Income
-54 -71 -98 -131 -102 -103 -164 -213 -154 -121 -34
Total Operating Income
-51 -35 -90 -120 -111 -94 -189 -204 -142 -110 -70
Total Gross Profit
1.73 45 14 21 26 31 37 45 62 37 42
Total Revenue
1.73 46 17 27 37 46 69 76 85 58 63
Operating Revenue
1.73 46 17 27 37 46 69 76 85 58 63
Total Cost of Revenue
0.00 1.13 3.66 6.13 11 15 32 31 23 21 21
Operating Cost of Revenue
0.00 1.13 3.66 6.13 11 15 32 31 23 21 21
Total Operating Expenses
111 80 103 141 137 125 225 249 204 147 113
Selling, General & Admin Expense
40 39 51 53 56 61 87 114 91 88 96
Research & Development Expense
71 41 52 87 81 64 129 135 106 57 12
Amortization Expense
- - - - - - - - 3.77 3.42 4.26
Other Operating Expenses / (Income)
0.00 -0.16 - - - 0.00 9.54 - 0.00 -4.55 0.00
Impairment Charge
- - - - - - - 0.00 3.14 3.69 0.00
Total Other Income / (Expense), net
-3.35 -5.17 -7.72 -11 9.16 -8.58 24 -9.90 -11 -10 37
Interest Expense
1.48 3.69 7.69 10 12 15 15 14 15 14 10
Interest & Investment Income
-1.43 -0.62 1.05 -0.29 2.56 7.94 40 1.40 3.00 2.68 30
Other Income / (Expense), net
-0.44 -0.86 -1.08 -0.18 18 -1.19 -0.45 2.34 1.02 0.68 17
Income Tax Expense
0.00 0.00 - - 0.00 0.14 0.47 0.45 0.52 0.31 -0.62
Preferred Stock Dividends Declared
- - - - - - - 8.03 8.03 9.89 8.70
Net Income / (Loss) Attributable to Noncontrolling Interest
-5.46 -16 -33 -58 -62 -56 -100 -127 -94 -75 -40
Basic Earnings per Share
($1.24) ($1.38) ($1.61) ($1.94) ($0.73) ($2.86) ($0.79) ($15.97) ($8.47) ($2.69) ($0.07)
Weighted Average Basic Shares Outstanding
39.15M 39.96M 41.66M 43.46M 54.71M 72.01M 81.70M 5.92M 8.11M 20.78M 27.90M
Diluted Earnings per Share
($1.24) ($1.38) ($1.61) ($1.94) ($0.73) ($2.86) $0.00 ($15.97) ($8.47) ($2.69) ($0.07)
Weighted Average Diluted Shares Outstanding
39.15M 39.96M 41.66M 43.46M 54.71M 72.01M 81.70M 5.92M 8.11M 20.78M 27.90M
Weighted Average Basic & Diluted Shares Outstanding
39.15M 39.96M 41.66M 43.46M 54.71M 72.01M 81.70M 133.19M 22.66M 32.96M 35.63M

Quarterly Income Statements for Fortress Biotech

This table shows Fortress Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-18 -13 -15 -9.65 -13 13 3.68 -22 108 -2.48 -7.85
Consolidated Net Income / (Loss)
-39 -29 -27 -26 -25 -12 8.83 -5.40 137 0.60 -8.25
Net Income / (Loss) Continuing Operations
-39 -29 -27 -26 -25 -12 8.83 -5.40 137 0.60 -8.25
Total Pre-Tax Income
0.00 -29 -27 -65 -25 -12 8.85 -31 142 0.92 -8.31
Total Operating Income
-37 -28 -22 -24 -22 -36 -6.81 -4.62 -7.74 -10 -7.19
Total Gross Profit
7.03 9.13 10 10 8.35 11 12 11 9.82 13 13
Total Revenue
13 15 15 15 13 16 18 16 16 19 19
Operating Revenue
13 15 15 15 13 16 18 16 16 19 19
Other Revenue
- - - - - - -0.00 - - 0.00 0.00
Total Cost of Revenue
6.00 5.73 4.47 4.68 4.79 4.94 5.76 5.44 6.22 6.14 5.88
Operating Cost of Revenue
6.00 5.73 4.47 4.68 4.79 4.94 5.76 5.44 6.22 6.14 5.88
Total Operating Expenses
44 37 32 34 31 48 19 15 18 23 20
Selling, General & Admin Expense
18 21 22 27 26 39 17 15 16 21 18
Research & Development Expense
25 13 9.45 9.93 3.94 8.13 0.21 -0.37 0.54 0.81 1.68
Amortization Expense
0.81 0.81 0.81 0.98 1.07 1.06 1.06 1.07 1.13 0.97 0.97
Total Other Income / (Expense), net
-2.46 -1.04 -4.53 -2.14 -2.37 25 16 -1.42 150 11 -1.12
Interest Expense
2.60 2.12 6.21 2.59 2.81 2.52 2.74 2.04 3.37 1.48 2.50
Interest & Investment Income
0.83 0.73 0.59 0.53 0.49 28 0.74 0.64 0.57 1.66 1.40
Other Income / (Expense), net
-0.69 0.35 1.09 -0.07 -0.06 -0.41 18 -0.02 153 11 -0.02
Income Tax Expense
- - 0.07 - 0.00 0.00 0.03 - 5.13 0.32 -0.06
Preferred Stock Dividends Declared
2.44 - 2.17 - 2.13 2.13 2.17 - 2.01 2.01 2.01
Net Income / (Loss) Attributable to Noncontrolling Interest
-24 -18 -14 -20 -14 -27 2.98 -1.46 27 1.07 -2.41
Basic Earnings per Share
($1.04) ($0.73) ($0.76) ($0.46) ($0.48) $0.50 $0.13 ($0.78) $3.44 ($0.08) ($0.23)
Weighted Average Basic Shares Outstanding
17.15M 18.32M 19.70M 20.78M 26.45M 26.88M 27.24M 27.90M 31.54M 31.79M 33.75M
Diluted Earnings per Share
($1.04) ($0.73) ($0.76) ($0.46) ($0.48) $0.45 $0.11 ($0.78) $2.82 ($0.08) ($0.23)
Weighted Average Diluted Shares Outstanding
17.15M 18.32M 19.70M 20.78M 26.45M 29.82M 33.10M 27.90M 38.41M 31.79M 33.75M
Weighted Average Basic & Diluted Shares Outstanding
23.34M 26.24M 31.03M 32.96M 33.00M 33.18M 34.47M 35.63M 36.65M 36.78M 37.17M

Annual Cash Flow Statements for Fortress Biotech

This table details how cash moves in and out of Fortress Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
48 -8.97 32 -29 72 82 73 -127 -98 -25 22
Net Cash From Operating Activities
-20 -46 -81 -99 -95 -84 -117 -179 -128 -80 -66
Net Cash From Continuing Operating Activities
-20 -46 -77 -97 -95 -83 -117 -179 -128 -80 -66
Net Income / (Loss) Continuing Operations
-54 -71 -98 -128 -102 -103 -165 -214 -154 -121 -33
Consolidated Net Income / (Loss)
-54 -71 -100 -142 -102 -103 -165 -214 -154 -121 -33
Depreciation Expense
0.03 0.94 0.73 1.39 1.92 2.28 2.63 3.11 2.23 1.04 0.40
Amortization Expense
0.31 1.81 3.68 3.09 6.05 8.67 8.08 6.34 6.80 5.48 5.66
Non-Cash Adjustments To Reconcile Net Income
28 15 19 19 3.43 14 1.27 26 29 42 -14
Changes in Operating Assets and Liabilities, net
5.34 7.48 0.81 7.79 -4.70 -4.81 36 -1.26 -12 -8.12 -25
Net Cash From Investing Activities
7.89 -6.06 -40 19 20 -7.16 41 -23 -2.10 -15 10
Net Cash From Continuing Investing Activities
7.89 -6.06 -40 9.04 7.01 -7.16 41 -23 -2.10 -15 10
Acquisitions
-12 -4.31 -3.67 -2.27 -8.25 -5.24 -12 -0.34 -8.04 -15 0.00
Sale of Property, Plant & Equipment
- - - - - - - 0.13 6.00 0.00 1.17
Divestitures
- - - - - 0.00 57 - - 0.00 8.96
Net Cash From Financing Activities
61 43 150 51 147 172 149 75 33 71 77
Net Cash From Continuing Financing Activities
61 43 154 51 147 172 149 75 33 71 77
Repayment of Debt
-0.86 -6.99 -3.79 -6.68 -1.65 -95 -22 -8.46 -83 -52 -6.19
Repurchase of Preferred Equity
-6.32 -2.84 0.00 -0.34 -0.58 -4.45 0.00 -1.19 -0.40 0.34 -0.27
Payment of Dividends
0.00 0.00 -0.30 -2.34 -2.56 -6.75 -8.78 -8.78 -8.77 -4.71 -0.66
Issuance of Debt
10 13 41 29 15 60 7.00 52 43 44 -0.08
Issuance of Common Equity
58 40 95 31 52 126 120 23 81 34 20
Other Financing Activities, net
0.22 -0.08 0.03 -0.31 79 54 53 19 1.36 50 64
Cash Interest Paid
0.00 0.00 0.78 4.73 5.90 8.82 6.92 9.42 7.95 7.16 7.39
Cash Income Taxes Paid
0.00 0.00 - - - 0.00 0.99 0.86 -0.06 0.12 0.05

Quarterly Cash Flow Statements for Fortress Biotech

This table details how cash moves in and out of Fortress Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
2.47 -7.57 -17 -2.10 34 -17 12 -6.84 176 -59 -44
Net Cash From Operating Activities
-25 -22 -20 -13 -20 -28 -6.11 -13 204 -59 -6.20
Net Cash From Continuing Operating Activities
-25 -22 -20 -13 -20 -28 -6.11 -13 204 -59 -6.20
Net Income / (Loss) Continuing Operations
-39 -29 -27 -26 -25 -12 8.83 -5.40 137 0.60 -8.25
Consolidated Net Income / (Loss)
-39 -29 -27 -26 -25 -12 8.83 -5.40 137 0.60 -8.25
Depreciation Expense
0.38 0.38 0.14 0.14 0.13 0.09 0.09 0.09 0.09 0.09 0.10
Amortization Expense
1.42 1.57 3.57 -1.09 1.36 1.52 1.38 1.40 2.58 1.19 1.04
Non-Cash Adjustments To Reconcile Net Income
6.01 7.62 8.55 20 5.78 -11 -11 2.15 7.87 -7.52 4.00
Changes in Operating Assets and Liabilities, net
5.82 -2.58 -5.63 -5.74 -2.14 -6.53 -4.95 -11 56 -54 -3.09
Net Cash From Investing Activities
0.00 - - -15 1.17 6.09 2.87 - 0.00 -0.08 -0.01
Net Cash From Continuing Investing Activities
0.00 - - -15 1.17 6.09 2.87 - 0.00 -0.08 -0.01
Purchase of Property, Plant & Equipment
- - - - - - - - - - -0.01
Net Cash From Financing Activities
28 14 2.71 26 52 4.52 15 5.71 -27 0.09 -38
Net Cash From Continuing Financing Activities
28 14 2.71 26 52 4.52 15 5.71 -27 0.09 -38
Repayment of Debt
0.00 - -52 -0.63 -0.63 -4.93 -0.57 -0.06 -14 - -15
Payment of Dividends
-2.18 -2.18 -0.18 -0.17 -0.17 -0.17 -0.17 -0.17 0.00 - -23
Issuance of Common Equity
13 28 -16 8.70 53 9.16 14 -56 0.15 -0.07 0.08
Other Financing Activities, net
17 -17 37 13 -0.13 0.58 1.69 62 1.13 0.16 0.05
Cash Interest Paid
1.66 1.88 1.87 1.76 3.32 0.60 1.75 1.71 1.76 1.21 1.97
Cash Income Taxes Paid
- - - 0.01 - - - - - - 0.02

Annual Balance Sheets for Fortress Biotech

This table presents Fortress Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
119 171 246 141 226 333 397 294 168 144 186
Total Current Assets
100 110 183 111 156 266 346 230 117 90 124
Cash & Equivalents
98 88 95 66 137 233 306 178 81 57 79
Accounts Receivable
0.00 1.83 7.76 5.50 14 24 23 28 15 10 30
Inventories, net
0.00 0.20 0.17 0.68 0.86 1.40 9.86 14 10 14 9.62
Prepaid Expenses
1.60 9.06 5.73 6.74 4.13 6.72 7.07 9.66 11 7.11 4.90
Plant, Property, & Equipment, net
0.31 7.38 7.12 12 12 12 15 13 6.51 3.26 2.52
Total Noncurrent Assets
18 54 56 18 58 55 35 51 44 51 59
Intangible Assets
1.25 17 0.88 1.42 7.38 15 13 27 20 32 28
Other Noncurrent Operating Assets
0.04 0.39 0.26 0.28 23 22 20 21 21 17 30
Other Noncurrent Nonoperating Assets
15 16 53 16 17 1.65 2.22 2.69 2.44 1.55 1.22
Total Liabilities & Shareholders' Equity
119 171 246 141 226 333 397 294 168 144 186
Total Liabilities
34 88 125 121 154 136 171 244 166 146 123
Total Current Liabilities
11 57 71 56 46 52 101 128 85 71 50
Short-Term Debt
0.00 2.03 13 19 7.22 0.00 0.81 2.95 - - 0.00
Accounts Payable
10 24 28 34 35 45 91 97 74 66 47
Current Deferred & Payable Income Tax Liabilities
- - - - 0.00 0.00 0.35 0.72 0.84 0.93 0.36
Other Current Liabilities
0.11 17 0.98 1.09 1.90 1.85 6.61 27 11 4.97 2.26
Total Noncurrent Liabilities
24 31 54 66 108 85 70 117 81 74 74
Long-Term Debt
23 23 39 60 82 60 43 92 61 58 52
Other Noncurrent Operating Liabilities
0.58 8.67 15 5.21 26 25 27 25 20 17 21
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
84 83 121 20 73 197 226 50 1.59 -1.64 62
Total Preferred & Common Equity
57 38 53 1.85 26 100 109 42 23 23 50
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
57 38 53 1.85 26 100 109 42 23 23 50
Common Stock
247 284 365 398 462 583 656 676 717 764 784
Retained Earnings
-190 -245 -312 -396 -436 -483 -547 -634 -695 -741 -734
Noncontrolling Interest
27 44 68 18 46 97 117 8.30 -21 -24 12

Quarterly Balance Sheets for Fortress Biotech

This table presents Fortress Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
165 146 127 178 160 181 357 317 280
Total Current Assets
117 103 86 127 110 119 295 246 210
Cash & Equivalents
84 76 59 91 74 86 256 197 152
Accounts Receivable
10 11 11 18 16 18 26 37 47
Inventories, net
11 9.69 12 12 13 12 9.29 8.16 7.77
Prepaid Expenses
12 4.65 2.58 4.73 6.96 2.34 4.84 4.02 2.96
Plant, Property, & Equipment, net
6.13 3.55 3.40 2.80 2.70 2.61 2.43 2.41 2.32
Total Noncurrent Assets
42 39 37 48 47 60 59 69 68
Intangible Assets
19 19 18 31 30 29 26 26 25
Other Noncurrent Operating Assets
20 18 17 16 16 30 31 42 42
Other Noncurrent Nonoperating Assets
2.06 2.06 2.06 1.22 1.22 1.22 1.22 1.22 1.22
Total Liabilities & Shareholders' Equity
165 146 127 178 160 181 357 317 280
Total Liabilities
169 160 140 146 123 116 155 111 103
Total Current Liabilities
88 76 70 74 58 54 103 62 72
Short-Term Debt
- - - 1.88 3.75 5.63 2.50 5.00 7.50
Accounts Payable
76 69 64 66 49 45 93 49 57
Current Deferred & Payable Income Tax Liabilities
0.84 0.81 0.85 0.95 0.98 1.01 5.42 5.18 5.12
Other Current Liabilities
10 5.82 4.96 4.56 4.21 2.27 2.49 2.51 2.51
Total Noncurrent Liabilities
81 85 70 72 65 62 51 49 31
Long-Term Debt
61 67 52 56 50 48 37 35 18
Other Noncurrent Operating Liabilities
19 18 17 16 15 14 14 14 13
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-3.94 -15 -13 32 37 65 202 206 177
Total Preferred & Common Equity
23 18 21 22 44 56 162 164 160
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
23 18 21 22 44 56 162 164 160
Common Stock
733 739 755 774 780 786 786 788 790
Retained Earnings
-710 -721 -734 -751 -736 -730 -624 -624 -630
Noncontrolling Interest
-27 -32 -34 10 -6.54 9.32 40 42 17

Annual Metrics And Ratios for Fortress Biotech

This table displays calculated financial ratios and metrics derived from Fortress Biotech's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
47,133,715.00 48,875,087.00 50,656,503.00 56,679,505.00 70,780,103.00 97,129,999.00 103,056,534.00 112,042,378.00 136,214,473.00 31,032,072.00 34,465,075.00
DEI Adjusted Shares Outstanding
314,225.00 325,834.00 337,710.00 377,863.00 471,867.00 647,533.00 687,044.00 746,949.00 9,080,965.00 31,032,072.00 34,465,075.00
DEI Earnings Per Adjusted Shares Outstanding
-154.12 -169.09 -198.03 -222.69 -84.68 -71.85 -94.18 -126.66 -7.56 -1.80 -0.05
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 2,563.91% -62.49% 55.88% 36.26% 24.49% 50.86% 10.11% 11.58% -31.76% 9.69%
EBITDA Growth
-145.43% 33.65% -157.40% -33.80% 27.05% -0.14% -110.96% -7.56% 31.01% 22.01% 54.47%
EBIT Growth
-146.80% 28.68% -149.99% -32.25% 23.14% -3.34% -97.98% -6.47% 29.77% 22.38% 51.65%
NOPAT Growth
-144.68% 29.77% -153.05% -33.63% 7.65% 14.93% -100.00% -7.97% 30.08% 22.46% 36.38%
Net Income Growth
-164.31% -32.31% -40.04% -42.17% 28.38% -1.30% -60.05% -29.78% 27.94% 21.60% 72.76%
EPS Growth
-121.43% -11.29% -16.67% -20.50% 62.37% -291.78% -60.05% -29.78% 46.96% 68.24% 97.40%
Operating Cash Flow Growth
-24.76% -124.81% -77.48% -21.58% 3.93% 11.88% -39.27% -53.94% 28.53% 37.46% 17.97%
Free Cash Flow Firm Growth
-104.61% -2.42% -30.90% -120.07% 5.44% 18.65% -24.85% -61.74% 20.48% 16.77% 10.49%
Invested Capital Growth
-96.79% 96.01% -6,633.55% 43.48% 88.47% 412.57% -1,001.86% 5.44% 42.29% 88.07% 1,461.59%
Revenue Q/Q Growth
228.76% 807.60% 0.00% 0.00% 6.20% 6.09% 7.04% -2.41% 4.37% -7.66% 1.47%
EBITDA Q/Q Growth
-18.57% 42.67% -79.44% -4.24% -144.65% 40.76% -59.60% 16.34% 16.53% 0.58% 31.70%
EBIT Q/Q Growth
-18.90% 39.07% -67.65% -5.05% -121.65% 38.04% -57.35% 16.67% 15.38% 2.87% 26.75%
NOPAT Q/Q Growth
-17.88% 39.96% -201.50% 12.28% 1.63% 6.06% -28.17% 5.18% 19.75% -4.07% 21.57%
Net Income Q/Q Growth
-26.72% -9.57% -4.96% -10.42% 36.69% -63.47% -41.11% 4.92% 15.59% 2.16% 38.86%
EPS Q/Q Growth
-21.57% -10.40% 12.50% -23.57% 28.43% -281.33% -41.11% 4.92% 45.00% -380.36% -118.92%
Operating Cash Flow Q/Q Growth
-20.99% -31.25% -3.69% -1.33% 41.37% -356.31% -18.52% -5.37% 9.15% 21.55% 0.55%
Free Cash Flow Firm Q/Q Growth
-12.28% 28.75% -72.27% 23.15% -97.18% 2.19% -7.64% 8.33% 18.37% -80.34% 25.52%
Invested Capital Q/Q Growth
-30.59% 84.32% -1,310.09% -143.58% 81.00% 201.31% -58.93% -117.33% 0.00% 88.21% 9.16%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 97.54% 78.79% 77.22% 71.25% 67.99% 53.36% 59.37% 72.91% 63.80% 66.92%
EBITDA Margin
-2,933.31% -73.06% -501.42% -430.38% -230.40% -185.34% -259.17% -253.18% -156.53% -178.90% -74.26%
Operating Margin
-2,927.64% -77.18% -520.71% -446.38% -302.54% -206.74% -274.08% -268.76% -168.43% -191.38% -111.00%
EBIT Margin
-2,953.01% -79.06% -526.94% -447.04% -252.18% -209.34% -274.73% -265.66% -167.22% -190.20% -83.84%
Profit (Net Income) Margin
-3,121.84% -155.05% -578.93% -528.00% -277.54% -225.85% -239.60% -282.42% -182.40% -209.54% -52.03%
Tax Burden Percent
100.00% 100.00% 102.38% 108.51% 100.00% 100.13% 100.29% 100.21% 100.34% 100.26% 98.15%
Interest Burden Percent
105.72% 196.12% 107.31% 108.84% 110.06% 107.74% 86.96% 106.08% 108.71% 109.89% 63.22%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -4,565.13% 0.00% 0.00% 0.00% 0.00% -312.07%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -4,537.38% 0.00% 0.00% 0.00% 0.00% -423.93%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 4,488.72% 0.00% 0.00% 0.00% 0.00% 203.33%
Return on Equity (ROE)
-69.62% -85.25% -98.13% -202.41% -220.34% -76.42% -77.95% -155.06% -597.36% 424,052.63% -108.74%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -1,684.31% 0.00% 0.00% 0.00% 0.00% -251.92%
Operating Return on Assets (OROA)
-49.02% -25.13% -43.62% -62.11% -50.28% -34.10% -51.78% -58.26% -61.20% -70.38% -32.17%
Return on Assets (ROA)
-51.83% -49.28% -47.92% -73.36% -55.34% -36.79% -45.16% -61.93% -66.76% -77.53% -19.96%
Return on Common Equity (ROCE)
-57.28% -48.60% -43.92% -78.55% -67.02% -35.88% -38.53% -84.52% -743.73% -336,824,261.31% -130.41%
Return on Equity Simple (ROE_SIMPLE)
-94.79% -185.19% -189.90% 0.00% -387.79% -102.64% -151.67% -512.72% -683.79% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-35 -25 -63 -84 -78 -66 -132 -142 -100 -77 -49
NOPAT Margin
-2,049.35% -54.03% -364.50% -312.47% -211.78% -144.72% -191.85% -188.13% -117.90% -133.97% -77.70%
Net Nonoperating Expense Percent (NNEP)
-22.23% -52.99% -32.92% -67.01% -45.69% -27.75% -14.38% -40.75% -100.22% -373.17% 111.86%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -159.57% -137.19% -42.89%
Cost of Revenue to Revenue
0.00% 2.46% 21.21% 22.78% 28.75% 32.01% 46.64% 40.63% 27.09% 36.20% 33.08%
SG&A Expenses to Revenue
2,335.92% 85.44% 295.14% 198.54% 151.77% 134.14% 126.24% 150.05% 107.65% 152.11% 152.38%
R&D to Revenue
4,115.18% 88.44% 304.35% 325.06% 222.03% 140.59% 187.33% 178.07% 125.51% 98.62% 18.81%
Operating Expenses to Revenue
6,451.10% 174.72% 599.50% 523.60% 373.79% 274.73% 327.44% 328.13% 241.34% 255.18% 177.93%
Earnings before Interest and Taxes (EBIT)
-51 -36 -91 -120 -92 -95 -189 -201 -141 -110 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-51 -34 -86 -116 -84 -85 -178 -192 -132 -103 -47
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.31 3.43 3.84 26.33 6.94 3.07 2.37 0.18 1.21 2.76 2.53
Price to Tangible Book Value (P/TBV)
2.37 54.04 3.91 112.31 9.66 3.59 2.68 0.51 12.13 0.00 5.67
Price to Revenue (P/Rev)
76.19 2.87 11.72 1.81 4.97 6.75 3.75 0.10 0.32 1.09 1.99
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 50.21 0.00 0.00 0.00 0.00 3.28
Enterprise Value to Revenue (EV/Rev)
47.18 2.37 11.03 2.34 4.64 4.68 1.64 0.00 0.00 0.68 1.76
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.28 0.30 0.44 4.03 1.24 0.30 0.19 1.89 38.35 -35.26 0.84
Long-Term Debt to Equity
0.28 0.27 0.33 3.06 1.14 0.30 0.19 1.83 38.35 -35.26 0.84
Financial Leverage
-1.08 -1.05 -1.10 -1.23 -1.14 -0.99 -1.08 -1.27 -2.11 409.86 -0.48
Leverage Ratio
1.34 1.73 2.05 2.76 3.98 2.08 1.73 2.50 8.95 -5,469.28 5.45
Compound Leverage Factor
1.42 3.39 2.20 3.00 4.38 2.24 1.50 2.66 9.73 -6,009.93 3.44
Debt to Total Capital
21.57% 22.84% 30.32% 80.11% 55.28% 23.29% 16.23% 65.43% 97.46% 102.92% 45.74%
Short-Term Debt to Total Capital
0.00% 1.89% 7.65% 19.22% 4.45% 0.00% 0.30% 2.04% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
21.57% 20.95% 22.67% 60.88% 50.82% 23.29% 15.92% 63.39% 97.46% 102.92% 45.74%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00%
Noncontrolling Interests to Total Capital
25.53% 41.36% 39.28% 18.03% 28.56% 37.64% 43.47% 5.74% -33.56% -43.29% 10.74%
Common Equity to Total Capital
52.91% 35.80% 30.40% 1.87% 16.16% 39.07% 40.30% 28.83% 36.10% 40.37% 43.52%
Debt to EBITDA
-0.46 -0.73 -0.61 -0.69 -1.06 -0.71 -0.25 -0.49 -0.46 -0.56 -1.12
Net Debt to EBITDA
1.53 2.01 0.92 0.03 0.69 2.26 1.47 0.44 0.15 -0.01 0.57
Long-Term Debt to EBITDA
-0.46 -0.67 -0.45 -0.52 -0.98 -0.71 -0.24 -0.48 -0.46 -0.56 -1.12
Debt to NOPAT
-0.66 -0.99 -0.83 -0.95 -1.16 -0.91 -0.33 -0.66 -0.61 -0.75 -1.07
Net Debt to NOPAT
2.19 2.72 1.27 0.04 0.75 2.90 1.99 0.59 0.20 -0.01 0.55
Long-Term Debt to NOPAT
-0.66 -0.91 -0.62 -0.72 -1.06 -0.91 -0.33 -0.64 -0.61 -0.75 -1.07
Altman Z-Score
-0.45 -1.17 -1.41 -5.84 -2.59 -0.71 -1.68 -4.58 -7.76 -8.89 -5.05
Noncontrolling Interest Sharing Ratio
17.72% 42.99% 55.24% 61.19% 69.59% 53.05% 50.58% 45.49% -24.50% 79,529.82% -19.93%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.45 1.94 2.56 2.00 3.43 5.14 3.43 1.80 1.38 1.27 2.49
Quick Ratio
9.28 1.67 1.94 1.59 3.30 4.97 3.25 1.62 1.13 0.95 2.20
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-32 -32 -42 -93 -88 -72 -89 -145 -115 -96 -86
Operating Cash Flow to CapEx
-7,200.71% -719.18% -12,547.07% -1,395.76% -4,049.51% -4,344.86% -2,552.34% -6,932.03% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-21.26 -8.76 -5.50 -9.00 -7.43 -4.67 -5.84 -10.60 -7.51 -7.07 -8.48
Operating Cash Flow to Interest Expense
-13.73 -12.42 -10.58 -9.56 -8.01 -5.46 -7.61 -13.15 -8.37 -5.93 -6.51
Operating Cash Flow Less CapEx to Interest Expense
-13.92 -14.14 -10.66 -10.24 -8.21 -5.59 -7.91 -13.34 -7.98 -5.93 -6.39
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.02 0.32 0.08 0.14 0.20 0.16 0.19 0.22 0.37 0.37 0.38
Accounts Receivable Turnover
0.00 0.00 3.60 4.06 3.85 2.43 2.92 2.94 3.86 4.47 3.14
Inventory Turnover
0.00 0.00 19.56 14.43 13.72 12.91 5.70 2.56 1.88 1.69 1.74
Fixed Asset Turnover
9.56 11.97 2.38 2.81 3.00 3.74 5.10 5.39 8.66 11.81 21.89
Accounts Payable Turnover
0.00 0.07 0.14 0.20 0.30 0.36 0.47 0.33 0.27 0.30 0.37
Days Sales Outstanding (DSO)
0.00 0.00 101.47 89.99 94.85 149.95 124.80 123.99 94.44 81.61 116.38
Days Inventory Outstanding (DIO)
0.00 0.00 18.66 25.30 26.60 28.27 64.08 142.45 194.23 215.35 209.81
Days Payable Outstanding (DPO)
0.00 5,609.53 2,590.77 1,842.88 1,207.20 1,010.92 773.87 1,115.49 1,363.25 1,215.53 982.33
Cash Conversion Cycle (CCC)
0.00 -5,609.53 -2,470.64 -1,727.59 -1,085.75 -832.69 -584.99 -849.06 -1,074.58 -918.57 -656.14
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-7.78 -0.31 -21 -12 -1.36 4.25 -38 -36 -21 -2.50 34
Invested Capital Turnover
-0.29 -11.37 -1.63 -1.65 -5.57 31.55 -4.04 -2.03 -2.96 -4.93 4.02
Increase / (Decrease) in Invested Capital
-3.83 7.47 -21 9.08 10 5.61 -43 2.09 15 18 36
Enterprise Value (EV)
81 109 190 63 170 213 113 -68 -14 39 111
Market Capitalization
132 132 202 49 182 308 258 7.34 27 63 126
Book Value per Share
$1.21 $0.79 $1.04 $0.03 $0.37 $1.03 $1.05 $0.37 $0.17 $0.73 $1.45
Tangible Book Value per Share
$1.18 $0.05 $1.02 $0.01 $0.27 $0.88 $0.93 $0.13 $0.02 ($0.29) $0.65
Total Capital
107 108 173 99 162 257 270 145 62 56 115
Total Debt
23 25 52 80 90 60 44 95 61 58 52
Total Long-Term Debt
23 23 39 60 82 60 43 92 61 58 52
Net Debt
-77 -68 -80 -3.61 -58 -191 -262 -84 -20 0.70 -27
Capital Expenditures (CapEx)
0.28 6.37 0.65 7.08 2.35 1.93 4.57 2.59 -5.94 0.00 -1.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.82 -36 -5.98 -8.44 -19 -19 -60 -73 -49 -38 -5.28
Debt-free Net Working Capital (DFNWC)
89 55 125 75 118 214 246 106 32 19 74
Net Working Capital (NWC)
89 53 112 56 111 214 245 103 32 19 74
Net Nonoperating Expense (NNE)
19 46 37 58 24 37 33 71 55 44 -16
Net Nonoperating Obligations (NNO)
-92 -83 -141 -32 -74 -193 -264 -86 -23 -0.85 -28
Total Depreciation and Amortization (D&A)
0.34 2.76 4.40 4.48 7.98 11 11 9.45 9.03 6.52 6.07
Debt-free, Cash-free Net Working Capital to Revenue
-511.24% -77.32% -34.69% -31.40% -51.88% -41.58% -86.51% -95.85% -57.76% -66.39% -8.35%
Debt-free Net Working Capital to Revenue
5,177.17% 119.84% 724.68% 277.77% 321.76% 470.16% 357.94% 139.50% 38.00% 32.89% 117.13%
Net Working Capital to Revenue
5,177.17% 115.42% 647.97% 206.80% 302.04% 470.16% 356.76% 135.61% 38.00% 32.89% 117.13%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($186.00) ($207.00) ($241.50) ($291.00) ($109.50) $0.00 ($606.00) ($14.55) ($8.47) ($2.69) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding
323.45K 335.47K 342.28K 408.68K 523.06K 0.00 719.51K 5.92M 8.11M 20.78M 27.90M
Adjusted Diluted Earnings per Share
($186.00) ($207.00) ($241.50) ($291.00) ($109.50) $0.00 ($606.00) $0.00 ($8.47) ($2.69) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding
323.45K 335.47K 342.28K 408.68K 523.06K 0.00 719.51K 5.92M 8.11M 20.78M 27.90M
Adjusted Basic & Diluted Earnings per Share
($186.00) ($207.00) ($241.50) ($291.00) ($109.50) $0.00 ($606.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
260.98K 266.42K 277.73K 289.75K 364.75K 0.00 544.67K 8.88M 22.66M 32.96M 35.63M
Normalized Net Operating Profit after Tax (NOPAT)
-35 -25 -63 -84 -78 -66 -132 -142 -97 -75 -49
Normalized NOPAT Margin
-2,049.35% -54.03% -364.50% -312.47% -211.78% -144.72% -191.85% -188.13% -115.30% -129.49% -77.70%
Pre Tax Income Margin
-3,121.84% -155.05% -565.46% -486.57% -277.54% -225.55% -238.92% -281.83% -181.79% -209.00% -53.01%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-34.35 -9.85 -11.82 -11.62 -7.80 -6.23 -12.35 -14.75 -9.23 -8.11 -5.25
NOPAT to Interest Expense
-23.84 -6.73 -8.18 -8.12 -6.55 -4.31 -8.62 -10.45 -6.51 -5.71 -4.86
EBIT Less CapEx to Interest Expense
-34.54 -11.58 -11.91 -12.31 -7.99 -6.35 -12.64 -14.94 -8.84 -8.11 -5.13
NOPAT Less CapEx to Interest Expense
-24.03 -8.46 -8.26 -8.81 -6.74 -4.43 -8.92 -10.64 -6.12 -5.71 -4.75
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% -0.30% -1.65% -2.52% -6.56% -5.33% -4.10% -5.69% -3.90% -2.02%
Augmented Payout Ratio
0.00% 0.00% -3.11% -1.65% -2.94% -6.62% -5.33% -4.10% -5.69% -3.90% -2.02%

Quarterly Metrics And Ratios for Fortress Biotech

This table displays calculated financial ratios and metrics derived from Fortress Biotech's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
22,661,664.00 23,343,262.00 26,241,092.00 31,032,072.00 32,960,978.00 32,997,058.00 33,181,891.00 34,465,075.00 35,629,702.00 36,646,210.00 36,778,131.00
DEI Adjusted Shares Outstanding
22,661,664.00 23,343,262.00 26,241,092.00 31,032,072.00 32,960,978.00 32,997,058.00 33,181,891.00 34,465,075.00 35,629,702.00 36,646,210.00 36,778,131.00
DEI Earnings Per Adjusted Shares Outstanding
-0.79 -0.57 -0.57 -0.31 -0.39 0.87 0.11 -0.63 3.04 -0.07 -0.21
Growth Metrics
- - - - - - - - - - -
Revenue Growth
4.84% -14.56% -57.90% -23.99% 0.84% 10.49% 20.52% 6.06% 22.06% 14.04% 8.68%
EBITDA Growth
27.35% 50.21% -156.27% 2.36% 41.08% -38.40% 171.33% 87.40% 807.35% 105.73% -149.20%
EBIT Growth
28.20% 48.80% -144.36% 11.91% 39.94% -34.44% 151.70% 80.67% 748.43% 101.99% -166.39%
NOPAT Growth
37.88% 44.54% -60.60% -22.02% 38.97% -31.25% 56.09% 80.69% 52.25% 74.41% 25.86%
Net Income Growth
29.24% 51.39% -148.92% 9.21% 36.73% 59.57% 133.07% 79.49% 655.51% 105.17% -193.51%
EPS Growth
0.00% 80.00% 19.15% -110.62% 53.85% 161.64% 114.47% -69.57% 687.50% -117.78% -309.09%
Operating Cash Flow Growth
41.26% 34.40% -19.55% 63.05% 22.94% -26.20% 69.54% 2.81% 1,142.02% -115.08% -1.42%
Free Cash Flow Firm Growth
-321.57% -1,412.95% 121.72% -21.06% -13.81% -53.97% -1,134.53% -12.95% 114.31% 41.93% 60.96%
Invested Capital Growth
28.76% 48.16% 0.00% 88.07% 93.60% 160.15% 247.05% 1,461.59% -743.01% 207.93% 57.94%
Revenue Q/Q Growth
-34.67% 14.01% -1.52% 3.64% -13.34% 24.92% 7.42% -8.80% -0.26% 16.71% 2.36%
EBITDA Q/Q Growth
-38.77% 28.11% 32.16% -44.25% 16.26% -68.88% 134.97% -125.48% 4,801.43% -98.63% -400.35%
EBIT Q/Q Growth
-36.72% 26.35% 23.44% -14.28% 6.78% -64.84% 129.44% -142.72% 3,227.66% -99.49% -1,081.09%
NOPAT Q/Q Growth
-86.45% 24.01% 20.49% -8.31% 6.74% -63.43% 73.40% 52.38% -130.67% 12.42% 22.93%
Net Income Q/Q Growth
-34.64% 26.14% 7.39% 1.42% 6.17% 52.80% 175.74% -161.14% 2,641.45% -99.56% -1,471.10%
EPS Q/Q Growth
-124.02% 29.81% -4.11% 39.47% -4.35% 193.75% -75.56% -809.09% 461.54% -102.84% -187.50%
Operating Cash Flow Q/Q Growth
27.33% 13.98% 8.15% 35.65% -51.57% -40.88% 77.83% -105.30% 1,725.09% -129.08% 89.55%
Free Cash Flow Firm Q/Q Growth
-27.48% -17.36% 113.14% -715.56% -19.85% -58.77% 11.68% 32.80% 115.19% -744.31% 40.62%
Invested Capital Q/Q Growth
-35.52% 8.81% 18.08% 88.21% 27.27% 956.44% 100.26% 9.16% -145.03% 412.84% 2.71%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
53.94% 61.45% 69.44% 69.14% 63.54% 69.91% 67.36% 66.17% 61.23% 67.18% 69.29%
EBITDA Margin
-272.10% -171.59% -118.21% -164.53% -158.99% -214.94% 69.96% -19.55% 921.35% 10.80% -31.68%
Operating Margin
-280.63% -187.06% -151.04% -157.84% -169.85% -222.22% -38.63% -28.73% -48.25% -53.46% -37.54%
EBIT Margin
-285.91% -184.69% -143.58% -158.33% -170.30% -224.73% 61.59% -28.85% 904.68% 3.93% -37.64%
Profit (Net Income) Margin
-299.49% -194.04% -182.47% -173.56% -187.92% -71.00% 50.07% -33.57% 855.23% 3.22% -43.08%
Tax Burden Percent
0.00% 100.00% 100.26% 40.42% 100.00% 100.00% 99.71% 17.56% 96.39% 65.29% 99.33%
Interest Burden Percent
0.00% 105.06% 126.76% 271.18% 110.35% 31.60% 81.53% 662.51% 98.07% 125.44% 115.24%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.29% 0.00% 3.61% 34.71% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -481.95% -80.78% 0.00% -75.33% -45.79%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -555.48% -65.88% 0.00% -83.26% -41.82%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 449.94% 31.60% 0.00% 61.56% 27.95%
Return on Equity (ROE)
-1,739.64% 704.33% 969.74% 424,052.63% -746.25% -784.31% -32.01% -49.18% 109.80% -13.77% -17.85%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -737.98% -369.22% -251.92% 0.00% -190.87% -115.80%
Operating Return on Assets (OROA)
-113.66% -93.46% -70.57% -58.58% -57.43% -87.28% 24.89% -11.07% 223.78% 1.13% -11.41%
Return on Assets (ROA)
-119.06% -98.19% -89.68% -64.22% -63.37% -27.58% 20.24% -12.88% 211.55% 0.92% -13.07%
Return on Common Equity (ROCE)
-6,666.86% -838.99% -1,610.52% -336,824,261.31% -1,183.29% -2,127.13% -47.01% -58.98% 86.23% -11.77% -15.91%
Return on Equity Simple (ROE_SIMPLE)
-599.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-26 -19 -15 -17 -16 -26 -6.79 -3.23 -7.46 -6.53 -5.04
NOPAT Margin
-196.44% -130.94% -105.72% -110.49% -118.90% -155.55% -38.52% -20.11% -46.51% -34.90% -26.28%
Net Nonoperating Expense Percent (NNEP)
-31.96% -41.48% -265.96% -81.87% -30.89% 83.88% 73.53% -14.90% 114.79% 7.93% -3.98%
Return On Investment Capital (ROIC_SIMPLE)
-44.53% -37.12% -38.92% -29.74% -17.22% -28.01% -5.73% -2.82% -3.09% -2.66% -2.49%
Cost of Revenue to Revenue
46.06% 38.55% 30.56% 30.86% 36.46% 30.09% 32.64% 33.83% 38.77% 32.82% 30.71%
SG&A Expenses to Revenue
137.69% 140.18% 150.34% 177.92% 195.32% 236.14% 98.77% 90.58% 99.10% 111.16% 93.02%
R&D to Revenue
190.63% 85.30% 64.57% 65.46% 29.97% 49.51% 1.18% -2.31% 3.37% 4.30% 8.76%
Operating Expenses to Revenue
334.57% 248.78% 220.47% 226.71% 233.40% 292.13% 105.99% 94.90% 109.48% 120.64% 106.83%
Earnings before Interest and Taxes (EBIT)
-37 -27 -21 -24 -22 -37 11 -4.64 145 0.74 -7.21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-35 -25 -17 -25 -21 -35 12 -3.14 148 2.02 -6.07
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.97 2.23 1.79 2.76 2.31 1.40 2.19 2.53 0.61 0.68 0.49
Price to Tangible Book Value (P/TBV)
12.77 0.00 11.45 0.00 0.00 4.33 4.51 5.67 0.73 0.81 0.58
Price to Revenue (P/Rev)
0.53 0.48 0.61 1.09 0.89 1.03 1.97 1.99 1.50 1.64 1.12
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 12.08 0.00 0.83 1.08 0.86
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.28% 0.00% 119.91% 92.18% 116.69%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 2.20 3.18 3.28 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.68 0.49 0.58 1.59 1.76 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-15.60 -4.59 -4.12 -35.26 1.79 1.44 0.82 0.84 0.19 0.19 0.14
Long-Term Debt to Equity
-15.60 -4.59 -4.12 -35.26 1.74 1.34 0.73 0.84 0.18 0.17 0.10
Financial Leverage
-5.29 1.48 0.66 409.86 -2.06 -1.45 -0.81 -0.48 -1.07 -0.74 -0.67
Leverage Ratio
26.98 -10.69 -9.98 -5,469.28 12.00 13.41 5.88 5.45 2.28 1.96 1.91
Compound Leverage Factor
0.00 -11.23 -12.65 -14,831.58 13.25 4.24 4.80 36.09 2.23 2.46 2.20
Debt to Total Capital
106.85% 127.85% 132.06% 102.92% 64.20% 58.99% 45.03% 45.74% 16.29% 16.12% 12.62%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 2.07% 4.11% 4.74% 0.00% 1.03% 2.04% 3.70%
Long-Term Debt to Total Capital
106.85% 127.85% 132.06% 102.92% 62.13% 54.88% 40.29% 45.74% 15.25% 14.08% 8.92%
Preferred Equity to Total Capital
0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-46.90% -61.96% -85.31% -43.29% 11.28% -7.18% 7.86% 10.74% 16.61% 17.07% 8.40%
Common Equity to Total Capital
40.05% 34.10% 53.24% 40.37% 24.52% 48.18% 47.11% 43.52% 67.10% 66.81% 78.97%
Debt to EBITDA
-0.52 -0.72 -0.51 -0.56 -0.66 -0.55 -0.78 -1.12 0.32 0.25 0.18
Net Debt to EBITDA
0.19 0.10 0.06 -0.01 0.37 0.21 0.48 0.57 -1.78 -0.99 -0.90
Long-Term Debt to EBITDA
-0.52 -0.72 -0.51 -0.56 -0.64 -0.51 -0.69 -1.12 0.30 0.22 0.13
Debt to NOPAT
-0.73 -0.98 -0.71 -0.75 -0.87 -0.73 -0.85 -1.07 -0.73 -1.40 -0.90
Net Debt to NOPAT
0.27 0.13 0.09 -0.01 0.49 0.28 0.52 0.55 4.03 5.56 4.45
Long-Term Debt to NOPAT
-0.73 -0.98 -0.71 -0.75 -0.84 -0.68 -0.76 -1.07 -0.69 -1.23 -0.64
Altman Z-Score
-5.90 -6.61 -7.83 -6.92 -5.43 -6.14 -4.03 -4.19 0.11 -1.23 -1.93
Noncontrolling Interest Sharing Ratio
-283.23% 219.12% 266.08% 79,529.82% -58.57% -171.21% -46.84% -19.93% 21.46% 14.54% 10.88%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.33 1.37 1.23 1.27 1.72 1.92 2.19 2.49 2.86 3.96 2.93
Quick Ratio
1.07 1.15 0.99 0.95 1.49 1.57 1.93 2.20 2.72 3.76 2.78
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-37 -43 5.71 -35 -42 -67 -59 -40 6.03 -39 -23
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -88,528.57%
Free Cash Flow to Firm to Interest Expense
-14.24 -20.49 0.92 -13.56 -15.03 -26.58 -21.56 -19.47 1.79 -26.34 -9.24
Operating Cash Flow to Interest Expense
-9.76 -10.29 -3.23 -4.98 -6.97 -10.95 -2.23 -6.15 60.53 -40.16 -2.48
Operating Cash Flow Less CapEx to Interest Expense
-9.76 -10.29 -3.23 -4.98 -6.56 -10.95 -2.23 -6.15 60.53 -40.16 -2.48
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.40 0.51 0.49 0.37 0.34 0.39 0.40 0.38 0.25 0.29 0.30
Accounts Receivable Turnover
4.51 5.96 5.76 4.47 4.06 4.41 4.30 3.14 3.02 2.59 2.14
Inventory Turnover
1.88 1.87 1.57 1.69 1.70 1.68 1.71 1.74 2.05 2.24 2.42
Fixed Asset Turnover
9.29 15.33 18.35 11.81 12.95 18.99 20.73 21.89 25.34 26.77 28.39
Accounts Payable Turnover
0.25 0.24 0.29 0.30 0.28 0.32 0.37 0.37 0.28 0.48 0.47
Days Sales Outstanding (DSO)
80.92 61.21 63.38 81.61 89.88 82.70 84.80 116.38 120.93 141.15 170.95
Days Inventory Outstanding (DIO)
193.98 195.44 233.23 215.35 214.13 217.88 213.66 209.81 177.90 162.76 150.95
Days Payable Outstanding (DPO)
1,478.13 1,503.24 1,276.13 1,215.53 1,323.86 1,135.82 992.65 982.33 1,300.43 758.49 784.39
Cash Conversion Cycle (CCC)
-1,203.23 -1,246.59 -979.53 -918.57 -1,019.85 -835.24 -694.18 -656.14 -1,001.60 -454.58 -462.50
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-28 -26 -21 -2.50 -1.82 16 31 34 -15 48 49
Invested Capital Turnover
-2.50 -2.18 -5.90 -4.93 -3.83 -11.52 12.51 4.02 -7.73 2.16 1.74
Increase / (Decrease) in Invested Capital
11 24 -21 18 27 41 52 36 -13 32 18
Enterprise Value (EV)
-3.99 -1.75 -2.35 39 29 34 99 111 -77 -2.89 -31
Market Capitalization
45 40 38 63 51 61 123 126 99 112 79
Book Value per Share
$1.02 $0.77 $0.81 $0.73 $0.72 $1.33 $1.68 $1.45 $4.71 $4.48 $4.35
Tangible Book Value per Share
$0.16 ($0.03) $0.13 ($0.29) ($0.28) $0.43 $0.82 $0.65 $3.94 $3.78 $3.68
Total Capital
57 52 40 56 91 91 119 115 242 246 203
Total Debt
61 67 52 58 58 54 53 52 39 40 26
Total Long-Term Debt
61 67 52 58 56 50 48 52 37 35 18
Net Debt
-22 -9.19 -6.38 0.70 -33 -21 -33 -27 -216 -157 -127
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 -1.17 0.00 0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-55 -48 -43 -38 -36 -18 -16 -5.28 -61 -8.09 -6.08
Debt-free Net Working Capital (DFNWC)
29 28 16 19 55 57 70 74 195 188 146
Net Working Capital (NWC)
29 28 16 19 53 53 64 74 192 183 139
Net Nonoperating Expense (NNE)
13 9.37 11 9.56 9.07 -14 -16 2.16 -145 -7.14 3.22
Net Nonoperating Obligations (NNO)
-24 -11 -8.44 -0.85 -34 -22 -34 -28 -218 -158 -128
Total Depreciation and Amortization (D&A)
1.80 1.95 3.71 -0.94 1.49 1.61 1.48 1.50 2.67 1.29 1.14
Debt-free, Cash-free Net Working Capital to Revenue
-64.53% -58.50% -68.65% -66.39% -62.71% -29.93% -25.92% -8.35% -92.58% -11.81% -8.69%
Debt-free Net Working Capital to Revenue
33.90% 33.77% 25.57% 32.89% 95.36% 95.42% 112.38% 117.13% 294.11% 275.30% 208.73%
Net Working Capital to Revenue
33.90% 33.77% 25.57% 32.89% 92.12% 89.10% 103.36% 117.13% 290.33% 268.00% 198.02%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.03) ($0.73) ($0.76) ($0.46) ($0.48) $0.50 $0.13 ($0.78) $3.44 ($0.08) ($0.23)
Adjusted Weighted Average Basic Shares Outstanding
17.15M 18.32M 19.70M 20.78M 26.45M 26.88M 27.24M 27.90M 31.54M 31.79M 33.75M
Adjusted Diluted Earnings per Share
$0.00 ($0.73) ($0.76) ($0.46) ($0.48) $0.45 $0.11 ($0.78) $2.82 ($0.08) ($0.23)
Adjusted Weighted Average Diluted Shares Outstanding
23.34M 18.32M 19.70M 20.78M 26.45M 29.82M 33.10M 27.90M 38.41M 31.79M 33.75M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.46) $0.00 $0.00 $0.00 ($0.78) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
23.34M 26.24M 31.03M 32.96M 33.00M 33.18M 34.47M 35.63M 36.65M 36.78M 37.17M
Normalized Net Operating Profit after Tax (NOPAT)
-26 -18 -15 -17 -16 -26 -6.79 -3.23 -7.46 -6.53 -5.04
Normalized NOPAT Margin
-196.44% -118.46% -105.72% -110.49% -118.90% -155.55% -38.52% -20.11% -46.51% -34.90% -26.28%
Pre Tax Income Margin
0.00% -194.04% -182.00% -429.35% -187.92% -71.00% 50.21% -191.14% 887.23% 4.93% -43.37%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-14.32 -12.93 -3.38 -9.25 -7.98 -14.65 3.96 -2.27 43.08 0.50 -2.89
NOPAT to Interest Expense
-9.84 -9.17 -2.49 -6.46 -5.57 -10.14 -2.48 -1.58 -2.21 -4.43 -2.02
EBIT Less CapEx to Interest Expense
-14.32 -12.93 -3.38 -9.25 -7.56 -14.65 3.96 -2.27 43.08 0.50 -2.89
NOPAT Less CapEx to Interest Expense
-9.84 -9.17 -2.49 -6.46 -5.15 -10.14 -2.48 -1.58 -2.21 -4.43 -2.02
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-6.34% -8.13% -5.45% -3.90% -2.53% -0.75% -1.23% -2.02% 0.39% 0.24% 18.83%
Augmented Payout Ratio
-6.34% -8.13% -5.45% -3.90% -2.53% -0.75% -1.23% -2.02% 0.39% 0.24% 18.83%

Financials Breakdown Chart

Key Financial Trends

Fortress Biotech’s Q2 2026 results show improving operating performance but continued cash-burn and earnings-quality concerns. Revenue increased to $18.7 million from $16.0 million in Q1 2026 and $16.4 million in the restated Q2 2025. Gross profit rose to $12.6 million, although the gross margin slipped to approximately 67.2% from 69.5% in Q1 and 69.9% in the year-ago quarter.

The company’s operating loss narrowed substantially to $10.0 million, compared with a $36.5 million operating loss in Q2 2025 and a $22.3 million loss in Q1 2024. However, Fortress recorded $10.7 million of net other income, which was important in producing $602,000 of consolidated net income. After preferred dividends and noncontrolling interests, the company still reported a $2.5 million loss attributable to common shareholders, or $0.08 per diluted share.

Liquidity remains stronger than it was in 2024 and much of 2025, but the latest quarter included significant cash usage. Cash and equivalents fell to $196.6 million from $255.8 million at the end of Q1 2026, primarily because operating activities consumed $59.3 million. Investors should also note that Q1’s $203.9 million of operating cash flow appears heavily influenced by working-capital movements and other adjustments rather than a recurring improvement in profitability.

  • Revenue growth continues: Q2 2026 revenue increased approximately 17% year over year and 17% sequentially, extending the improvement from the $13.0 million reported in Q1 2024.
  • Operating losses have narrowed: The $10.0 million Q2 2026 operating loss was materially better than the $36.5 million loss in Q2 2025 and the $22.3 million loss in Q1 2024.
  • Gross profit remains substantial: Fortress generated $12.6 million of gross profit in Q2 2026, with a gross margin above 67%, supporting the potential for operating leverage if revenue expands.
  • Balance-sheet liquidity is improved over the longer term: Cash of $196.6 million remains well above the $58.9 million reported in Q3 2024 and the $74.4 million reported in Q2 2025.
  • Leverage has declined from earlier periods: Total debt was approximately $39.6 million at June 30, 2026, versus more than $72 million at Q2 2024 and approximately $85 million at Q1 2024.
  • Q2 net income depended on non-operating items: $10.7 million of net other income helped offset the operating loss, so the quarter’s consolidated profit does not yet demonstrate sustainable operating profitability.
  • Working-capital balances are volatile: Accounts receivable increased to $36.8 million in Q2 2026 from $25.5 million in Q1, while accounts payable fell to $49.3 million from $93.0 million. These movements contributed to the sharp swing in operating cash flow.
  • Operating cash flow remains a major concern: The company used $59.3 million in operating cash during Q2 2026, following $27.6 million of operating cash burn in Q2 2025 and negative operating cash flow in most of the supplied quarters.
  • Common shareholders remain exposed to losses and capital claims: Q2’s $602,000 consolidated profit became a $2.5 million common-shareholder loss after $2.0 million of preferred dividends and $1.1 million attributable to noncontrolling interests.
  • Accumulated losses remain significant: Retained earnings were negative $624.1 million at June 30, 2026, highlighting the company’s long history of losses despite recent revenue and operating improvements.

Overall, Fortress Biotech is showing better revenue growth, lower operating expenses and reduced debt compared with earlier periods. Nevertheless, the investment case remains dependent on continued revenue expansion, improving core profitability and a substantial reduction in cash burn. The restated 2024 and 2025 figures also indicate that investors should focus on recurring operating results rather than isolated gains or losses from non-operating items.

11/16/26 06:07 PM ETAI Generated. May Contain Errors.

Fortress Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Fortress Biotech's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Fortress Biotech's net income appears to be on a downward trend, with a most recent value of -$32.92 million in 2025, rising from -$53.88 million in 2015. The previous period was -$120.86 million in 2024.

Fortress Biotech's total operating income in 2025 was -$70.22 million, based on the following breakdown:
  • Total Gross Profit: $42.34 million
  • Total Operating Expenses: $112.56 million

Over the last 10 years, Fortress Biotech's total revenue changed from $1.73 million in 2015 to $63.26 million in 2025, a change of 3,565.2%.

In the past 10 quarters, Fortress Biotech's cash and equivalents has ranged from $58.85 million in Q3 2024 to $255.84 million in Q1 2026, and is currently $152.19 million as of their latest financial filing in Q3 2026.

Fortress Biotech had total debt of $52.42 million at the end of 2025, a 9.6% decrease from 2024, and a 126.2% increase since 2015.

Over the last 10 years, Fortress Biotech's book value per share changed from 1.21 in 2015 to 1.45 in 2025, a change of 20.0%.



Financial statements for NASDAQ:FBIOP last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners